HaploX CUBE-ctDNA sequencing technology can accurately identify trace quantities of circulating tumor DNA in the blood, with sensitivity as low as 0.05%!
HaploX has the world's most advanced platforms: Illumina's NextSeq, HiSeq X Ten, NovaSeq 6000 serial sequencing and digital PCR, with sequencing throughput capability ranking second in the world, and tumor gene data output ranking first in China.
HaploX was formed by a group of young, talented scientists specializing in genomics, bioinformatics, molecular biology, medicine, machine learning, big data mining and other related areas.
June 28, 2018, HaploX announced the completion of several hundred million B round financing. the industry leader—Shenzhen Capital Group Co., Ltd. assisted HaploX in researching cancer precision medicine.<read more>
HaploX CTO Shifu Chen revealed that sample store time might affect the result of TMB test.<read more>
HaploX combined Shenzhen People's Hospital team to explore early detection of colorectal cancer.<read more>
HaploX joined the team of the School of Medicine from New Mexico University and the Shenzhen People's Hospital in advance to point out the signs of tumor recurrence.<read more>
June 2018, HaploX Laboratory was given ten out of ten for CAP competence verification once again.<read more>
Nov 14, 2017. HapLab passed the external quality test project Lung Cancer (NSCLC) conducted for EMQN excellently.<read more>